PARP1 and cancer: Although there are an increasing number of clinical trials evaluating PARP inhibitors as monotherapy or in combination with other agents in several different cancer types54, the lack of predictive biomarkers in this space have substantially limited our ability to maximize the therapeutic window for patients in this setting.